Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Astrazeneca (AZNCF) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Astrazeneca (AZNCF) over the last 16 years, with Q4 2025 value amounting to 17.93%.

  • Astrazeneca's EBITDA Margin rose 186700.0% to 17.93% in Q4 2025 from the same period last year, while for Dec 2025 it was 22.02%, marking a year-over-year increase of 104800.0%. This contributed to the annual value of 22.02% for FY2025, which is 104800.0% up from last year.
  • According to the latest figures from Q4 2025, Astrazeneca's EBITDA Margin is 17.93%, which was up 186700.0% from 16.95% recorded in Q3 2025.
  • In the past 5 years, Astrazeneca's EBITDA Margin registered a high of 1084.18% during Q4 2022, and its lowest value of 547.19% during Q3 2022.
  • Over the past 5 years, Astrazeneca's median EBITDA Margin value was 14.65% (recorded in 2021), while the average stood at 44.48%.
  • As far as peak fluctuations go, Astrazeneca's EBITDA Margin skyrocketed by 10903900bps in 2022, and later crashed by -10693700bps in 2023.
  • Quarter analysis of 5 years shows Astrazeneca's EBITDA Margin stood at 6.21% in 2021, then soared by 17556bps to 1084.18% in 2022, then tumbled by -99bps to 14.8% in 2023, then plummeted by -105bps to 0.75% in 2024, then soared by 2505bps to 17.93% in 2025.
  • Its last three reported values are 17.93% in Q4 2025, 16.95% for Q3 2025, and 24.6% during Q2 2025.